PD-L1 and PD-L1 Inhibitors Infographic
PD-L1 and PD-L1 Inhibitors Infographic

PD-L1 and PD-L1 Inhibitors Overview:


Programmed death 1 (PD-1) proteins bind with two ligands, namely Programmed death-ligand 1 (PD-L1) and Programmed death-ligand 2 (PD-L2). Programmed death-ligand 1 (PD-L1) in humans is encoded by the CD274 gene. PD-L1 is also known as cluster of differentiation 274 (CD274).


PD-L1 and PD-L1 Inhibitors Therapies: 200+


PD-L1 and PD-L1 Inhibitors Companies: 180+ 


Key PD-L1 and PD-L1 Inhibitors Companies

  • Merck
  • Laekna Therapeutics
  • Genentech
  • Tracon Pharmaceuticals Inc.
  • Celgene
  • MedImmune
  • Hangzhou Sumgen Biotech
  • Lepu Biopharma
  • Harbour BioMed
  • Curis
  • BeiGene
  • Apollomics

And several others.


PD-1 AND PD-L1 INHIBITORS Report Assessment

  • Company Analysis
  • Therapeutic Assessment
  • Approved/Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs


PD-L1 and PD-L1 Inhibitors Therapeutic Assessment:

  • By Product Type
  • By Stage and Product Type
  • By Route of Administration
  • By Stage and Route of Administration
  • By Molecule Type
  • By Stage and Molecule Type


Related Reports:

PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology And Market Forecast - 2032